OncoCyte Corp (NYSEAMERICAN:OCX) saw a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 1,256,555 shares, a growth of 243.9% from the January 15th total of 365,397 shares. Approximately 6.8% of the company’s stock are short sold. Based on an average daily trading volume, of 4,949,763 shares, the short-interest ratio is presently 0.3 days.
Shares of OncoCyte stock traded down $0.13 on Monday, reaching $3.87. 636,396 shares of the company were exchanged, compared to its average volume of 2,368,775. OncoCyte has a 1-year low of $1.10 and a 1-year high of $6.92.
OncoCyte (NYSEAMERICAN:OCX) last announced its quarterly earnings results on Tuesday, November 13th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02.
A hedge fund recently raised its stake in OncoCyte stock. Vanguard Group Inc boosted its holdings in OncoCyte Corp (NYSEAMERICAN:OCX) by 3.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 410,275 shares of the biotechnology company’s stock after acquiring an additional 15,115 shares during the quarter. Vanguard Group Inc owned 1.01% of OncoCyte worth $1,026,000 at the end of the most recent quarter.
OCX has been the topic of several research reports. Lake Street Capital upped their price objective on OncoCyte from $4.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, January 29th. Janney Montgomery Scott upgraded OncoCyte from a “neutral” rating to a “buy” rating in a research note on Tuesday, January 29th. Zacks Investment Research upgraded OncoCyte from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research note on Friday, January 25th. Finally, initiated coverage on OncoCyte in a research note on Monday, October 29th. They set a “positive” rating on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. OncoCyte currently has an average rating of “Buy” and a consensus target price of $5.33.
TRADEMARK VIOLATION NOTICE: “OncoCyte Corp (OCX) Short Interest Update” was posted by Macon Daily and is the property of of Macon Daily. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://macondaily.com/2019/02/11/oncocyte-corp-ocx-short-interest-update.html.
OncoCyte Company Profile
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.
Read More: What is Cost of Capital?
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.